Compare PTEN & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTEN | TLX |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.6B |
| IPO Year | 1995 | N/A |
| Metric | PTEN | TLX |
|---|---|---|
| Price | $9.71 | $10.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $10.80 | ★ $21.13 |
| AVG Volume (30 Days) | ★ 10.4M | 195.1K |
| Earning Date | 04-22-2026 | 08-19-2026 |
| Dividend Yield | ★ 3.24% | N/A |
| EPS Growth | ★ 90.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,826,624,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.34 | N/A |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.10 | $6.28 |
| 52 Week High | $13.08 | $16.85 |
| Indicator | PTEN | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 52.42 |
| Support Level | $9.26 | $9.42 |
| Resistance Level | $12.59 | $11.38 |
| Average True Range (ATR) | 0.41 | 0.27 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 70.35 | 42.99 |
Patterson-UTI Energy Inc is a Texas based provider of drilling and completion services to oil and natural gas exploration and production companies, offering contract drilling, integrated well completion, directional drilling services, and specialized drill bit solutions. The Company operates through three segments: Drilling Services, Completion Services, and Drilling Products. Drilling Services includes contract and directional drilling, Completion Services generates maximum revenue and includes hydraulic fracturing and related support services, and Drilling Products includes the manufacturing and distribution of drill bits. The Company operates in the United States, Canada, Colombia, and Other Countries, with the majority of revenue coming from the United States.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.